Transcriptomic analysis of the effect of trastuzumab in human iPSC-CMs. Transcriptomic analysis of the effect of trastuzumab in human iPSC-CMs

We used human iPSC-CMs generated from healthy individuals and performed RNA-sequencing after 7 days of trastuzumab treatment to examine the mechanism associated with contraction dysfunction in iPSC-CMs after trastuzumab treatment. Transcriptome analysis revealed the key role of an altered energy metabolism pathway for cardiomyocytes in the disease pathogenesis. Overall design: RNA profiling of 6 samples of trastuzumab- and no drug (control)-treated human iPSC-CMs